Summary:on day 35. When patients whose specimens tested positive for CMV by shell vial culture were treated with ganciclovir prophylactically, it prevented the development of CMV-IP From 1992 to 1995, 105 patients received PBSCT in our hospitals and we observed no incidence of CMV-pneufrom asymptomatic CMV infection. There are, however, few reports of the development to clinical CMV infection in monia. To clarify whether activation of CMV occurs in these patients, shell vial cultures, CMV antigenemia and patients receiving peripheral blood stem cell transplantation (PBSCT). From 1992 to 1995, 105 patients with leukemia, lymphoma every 1 to 2 weeks after transplantation to determine or solid tumors of advanced stage received PBSCT in our whether and when CMV was activated. Two patients hospitals. Seventeen patients were monitored for CMV actitested positive transiently by DNA-PCR but negative vation by three viral detection methods on day 35, and six throughout by both antigenemia and RT-PCR. These patients were monitored every 1 to 2 weeks. Details of 17 results suggest that the risk of CMV infection is low patients are given in Table 1. For prophylaxis of CMV because the incidence of CMV activation in patients infection, all patients received irradiated blood products receiving PBSCT is low.which were depleted of leukocytes by filters. They were Keywords: CMV; interstitial pneumonia; PBSCT; antialso treated with acyclovir at a dose of 15 mg/kg/day for genemia assay; shell vial culture method; RT-PCR method 30 days and anti-CMV antibody hyperimmune globulin at a dose of 200 mg/kg once a week for 3 months, and once every 2 weeks for the next 3 months after transplantation. 5CMV interstitial pneumonia (IP) is a significant complication after allogenic BMT (alloBMT). The incidence of Samples CMV-IP was about 20% and the mortality rate about 80% over a 10-year period.1-3 Prevention and treatment of Bronchoalveolar lavage (BAL) samples, peripheral blood CMV-IP is an important factor in improving the prognosis leukocyte (polymorphonuclear cells (PMNC) and monoof alloBMT patients. Recently, combined therapy with gannuclear cells (MNC)) samples and urine samples were ciclovir and anti-CMV hyperimmune globulin in the early taken from the patients on day 35 after transplantation. In stages of CMV-IP has been shown to improve survival, and addition, six of the patients were evaluated for the presence the mortality rate of such patients could be reduced to 10-of CMV antigen and DNA in PBLC using antigenemia and 20%. [4][5][6][7] To further reduce the mortality rate, it is necessary PCR methods every 1 to 2 weeks after transplantation. The to prevent the development to CMV-IP from asymptomatic BAL fluid was centrifuged and divided into supernatant CMV infection. 5,6 Schmidt et al 8 evaluated 104 patients (BALF) and pellet-containing BAL cells (BALC). BALF who had received alloBMT and from whom BAL was taken and BALC were prepared for CMV testing with shell vial culture and PCR methods. 5 × 10 4 cells obtained from cytospins ...
Our results suggest that urine levels of the thrombin-cleaved isoform of OPN may reflect the severity of active inflammatory arthritis in patients with RA.
It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We here evaluated the efficacy of molnupiravir in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron variant surge in Fukushima Prefecture, Japan. We enrolled patients with mild-to-moderate COVID-19 who were admitted to hospitals between January and April, 2022. Clinical deterioration after admission was compared between molnupiravir users (n = 230) and non-users (n = 690) after 1:3 propensity score matching. Additionally, we performed forward stepwise multivariate logistic regression analysis to evaluate the association between clinical deterioration after admission and molnupiravir treatment in the 1:3 propensity score-matched subjects. The characteristics of participants in both groups were balanced as indicated by covariates with a standardized mean difference of < 0.1. Regarding comorbidities, there was no imbalance between the two groups, except for the presence of hypertension, dyslipidemia, diabetes mellitus, and cardiac disease. The clinical deterioration rate was significantly lower in the molnupiravir users compared to the non-users (3.90% vs 8.40%; P = 0.034). Multivariate logistic regression analysis demonstrated that receiving molnupiravir was a factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.206–0.973; P = 0.042), independent of other covariates. This real-world study demonstrates that molnupiravir contributes to the prevention of deterioration in COVID-19 patients after hospitalization during the Omicron variant phase.
The ICGA kit has moderate sensitivity and high specificity, indicating clinical utility in the diagnosis of herpetic epithelial keratitis.
BACKGROUND: Due to the dissemination of vaccination against severe acute respiratory syndrome coronavirus 2 in the elderly, the virus-susceptible subjects have shifted to unvaccinated non-elderlies. The risk factors of COVID-19 deterioration in non-elderly patients without respiratory failure have not yet been determined. This study was aimed to create simple predicting method to identify such patients who have high risk for exacerbation. METHODS: We analyzed the data of 1675 patients aged under 65 years who were admitted to hospitals with mild-to-moderate COVID-19. For validation, 324 similar patients were enrolled. Disease progression was defined as administration of medication, oxygen inhalation and mechanical ventilator starting one day or longer after admission. RESULTS: The patients who exacerbated tended to be older, male, had histories of smoking, and had high body temperatures, lower oxygen saturation, and comorbidities such as diabetes/obesity and hypertension. Stepwise logistic regression analyses revealed that comorbidities of diabetes/obesity, age ≥ 40 years, body temperature ≥ 38 degree, and oxygen saturation < 96% (DOATS) were independent risk factors of worsening COVID-19. As a result two predictive scores were created: DOATS score, which includes all the above risk factors; and DOAT score, which includes all factors except for oxygen saturation. In the original cohort, the areas under the receiver operating characteristic curve of the DOATS and DOAT scores were 0.789 and 0.771, respectively. In the validation, the areas were 0.702 and 0.722, respectively. CONCLUSION: We established two simple prediction scores that can quickly evaluate the risk of progression of COVID-19 in non-elderly, mild/moderate patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.